FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  AULT MILTON C III
 2. Date of Event Requiring Statement (Month/Day/Year)
06/14/2021		 3. Issuer Name and Ticker or Trading Symbol
Alzamend Neuro, Inc. [ALZN]
(Last)
(First)
(Middle)
3802 SPECTRUM BOULEVARD, SUITE 112C		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

TAMPA, FL 33612		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 10,000,000
I
By Ault Life Sciences Fund, LLC (1)
Common Stock 3,094,555
I
By Digital Power Lending, LLC (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants 04/30/2019 04/29/2024 Common Stock 5,000,000 $ 3 I By Ault Life Sciences Fund, LLC (1)
Warrants 03/09/2021 03/08/2026 Common Stock 1,350,000 $ 3 I By Digital Power Lending, LLC (2)
Series A Convertible Preferred Stock   (3)   (3) Common Stock 15,000,000 $ (3) I By Ault Life Sciences, Inc.
Stock Options (Right to Buy)   (4) 04/29/2026 Common Stock 2,500,000 $ 0.0004 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
AULT MILTON C III
3802 SPECTRUM BOULEVARD, SUITE 112C
TAMPA, FL 33612		     X    

Signatures

/s/ Milton C. Ault, III 06/14/2021
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.
(2) Digital Power Lending, LLC ("DPL") is a wholly-owned subsidiary of Ault Global Holdings, Inc. ("AGH") Mr. Ault, the Executive Chairman of AGH, is deemed to have voting and investment power with respect to the securities held of record by DPL.
(3) The Series A Convertible Preferred Stock (the "Series A Preferred Stock") shall automatically convert into 15,000,000 shares of Common Stock upon the closing of the initial public offering without payment of further consideration. Mr. Ault has sole voting and investment power with respect to the shares of Series A Preferred Stock held of record by Ault Life Sciences, Inc.
(4) Mr. Ault was granted stock options to purchase 2,500,000 shares of Common Stock, which options are exercisable at an exercise price of $0.004 and are currently vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.